Monaco Gaspare, Cacioppo Viviana, Consonni Dario, Troiano Pasquale
Ophthalmology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy.
Eur J Ophthalmol. 2011 May-Jun;21(3):243-50. doi: 10.5301/EJO.2010.5730.
To determine the effects of 2 artificial tear formulas on the ocular surface in patients with glaucoma using topical preserved beta-blockers (BB) or prostaglandins (PG).
This was a prospective, comparative, randomized, double-blind study with a crossover design. Twenty patients with dry eye were divided into 2 groups based on glaucoma treatment: BB (10 subjects) or PG (10 subjects). Each group was administered a 4-week course of unpreserved isotonic (300 mOsm/L) solution containing 0.2% sodium hyaluronate (SH) or a preserved isotonic (295-305 mOsm/L) solution containing 0.5% carboxymethylcellulose and 0.9% glycerin as compatible solute (CMCs) administered QID. After a 2-week washout period, the course of treatment was reversed. The primary efficacy criteria consisted of assessing symptoms according to the Ocular Surface Disease Index© (OSDI); the secondary efficacy criteria consisted of evaluating tear film confocal microscopy, central corneal thickness (CCT), and lissamine corneal and conjunctival staining (Oxford Grading System Score [OGSS]).
Within each group, only CMCs induced a significant improvement in OSDI and OGSS compared to baseline values: OSDI -20.5, p<0.0001; OGSS -0.9, p<0.0001. Tear film confocal microscopy improved after treatment, especially in case of patients who were administered CMCs. No difference in CCT was noticed for any subject.
This study demonstrates for the first time that the use of concomitant CMCs in the management of glaucoma undergoing treatment with BB or PG may assist in tear film production and could lead to better compliance with intraocular pressure-lowering medication and ultimately better prognosis.
确定两种人工泪液配方对使用局部保存的β受体阻滞剂(BB)或前列腺素(PG)的青光眼患者眼表的影响。
这是一项采用交叉设计的前瞻性、比较性、随机、双盲研究。20名干眼患者根据青光眼治疗方法分为两组:BB组(10名受试者)和PG组(10名受试者)。每组接受为期4周的不含防腐剂的等渗(300 mOsm/L)溶液治疗,该溶液含有0.2%透明质酸钠(SH),或接受含有0.5%羧甲基纤维素和0.9%甘油作为相容性溶质(CMCs)的保存等渗(295 - 305 mOsm/L)溶液治疗,每日4次。经过2周的洗脱期后,治疗过程颠倒。主要疗效标准包括根据眼表疾病指数(OSDI)评估症状;次要疗效标准包括评估泪膜共聚焦显微镜检查、中央角膜厚度(CCT)以及丽丝胺绿角膜和结膜染色(牛津分级系统评分[OGSS])。
在每组中,与基线值相比,仅CMCs可使OSDI和OGSS有显著改善:OSDI -20.5,p<0.0001;OGSS -0.9,p<0.0001。治疗后泪膜共聚焦显微镜检查有所改善,尤其是接受CMCs治疗的患者。未观察到任何受试者的CCT有差异。
本研究首次表明,在接受BB或PG治疗的青光眼患者管理中使用CMCs可能有助于泪膜生成,并可能导致更好地依从降眼压药物治疗,最终改善预后。